Takeda's oral Velcade successor enters Phase III for myeloma
This article was originally published in Scrip
Takeda and its Millennium oncology operation have begun a Phase III development programme for ixazomib citrate (MLN9708), the first oral proteasome inhibitor to enter clinical trials and a possible successor to the firms' big-selling multiple myeloma drug Velcade (bortezomib).
You may also be interested in...
CEO breaks down to Scrip how the Hong Kong-based company managed its way through the coronavirus outbreak in China, saying improvisation was critical.
Japanese ICT giant applies novel advanced computing techniques with a US venture partner to more rapidly identify lead molecules from a huge virtual space.
A busy stretch of deal-making across Asia all includes transactions involving Innovent, Alector, Ono, Numab, Alphamab, 3DMed, Healios, Athersys, Laekna, Novartis, Asahi Kasei, SBI Biotech, Glenmark, Hindustan Unilever, Hanlim, Alteogen, Ildong, Evotec, AJU Pharm, Ribomec, Tyligand, Context